ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.1108
0.00%
Brent Oil
84.39
0.00%
Bitcoin
64,259.52
0.27%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. OptiNose Inc (OPTN)

  7. OptiNose Inc (OPTN) Noticias

OPTN

OptiNose (OPTN)

OptiNose Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:OPTN
FechaHoraFuenteTítuloSímboloCompañía
18/06/202416:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
06/06/202415:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
29/05/202414:32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
20/05/202413:33Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OPTNOptiNose Inc
17/05/202411:00GlobeNewswire Inc.Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:OPTNOptiNose Inc
14/05/202408:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OPTNOptiNose Inc
14/05/202406:00GlobeNewswire Inc.Optinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
10/05/202413:56GlobeNewswire Inc.Optinose Announces Reporting Date for First Quarter 2024 Financial ResultsNASDAQ:OPTNOptiNose Inc
09/05/202406:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OPTNOptiNose Inc
09/05/202406:00GlobeNewswire Inc.Optinose Announces $55 Million Registered Direct OfferingNASDAQ:OPTNOptiNose Inc
25/04/202406:00GlobeNewswire Inc.Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionNASDAQ:OPTNOptiNose Inc
04/04/202415:01GlobeNewswire Inc.Optinose to Present at the Needham Virtual Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
15/03/202414:34GlobeNewswire Inc.XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsNASDAQ:OPTNOptiNose Inc
07/03/202415:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OPTNOptiNose Inc
07/03/202406:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OPTNOptiNose Inc
07/03/202406:00GlobeNewswire Inc.Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
29/02/202415:40GlobeNewswire Inc.Optinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
18/01/202411:00GlobeNewswire Inc.Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeNASDAQ:OPTNOptiNose Inc
06/12/202307:48Dow Jones NewsOptinose Shares Slide Premarket as FDA Extends Xhance ReviewNASDAQ:OPTNOptiNose Inc
06/12/202306:00GlobeNewswire Inc.Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCENASDAQ:OPTNOptiNose Inc
22/11/202308:00GlobeNewswire Inc.Optinose to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
09/11/202306:00GlobeNewswire Inc.Optinose Reports Third Quarter 2023 Financial Results and Operational UpdatesNASDAQ:OPTNOptiNose Inc
27/10/202307:00GlobeNewswire Inc.Optinose Announces Reporting Date for Third Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
22/09/202308:01GlobeNewswire Inc.Optinose to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
17/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OPTNOptiNose Inc
10/08/202315:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OPTNOptiNose Inc
10/08/202306:00GlobeNewswire Inc.Optinose Reports Second Quarter 2023 Financial Results and Operational UpdatesNASDAQ:OPTNOptiNose Inc
27/07/202306:00GlobeNewswire Inc.Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 MillionNASDAQ:OPTNOptiNose Inc
20/06/202312:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPTNOptiNose Inc
16/06/202315:08GlobeNewswire Inc.Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPTNOptiNose Inc
 Showing the most relevant articles for your search:NASDAQ:OPTN

Su Consulta Reciente

TG
YEBG
Kreditanstalt fur Wieder...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados